It’s a bit cryptic …
From the quarterly on the 30th Jan it was said ….
“There were preliminary signs of efficacy from the 14 patients dosed in the Phase 1b trial.”
From today’s Ann …
Of these fourteen patients seven (7) patients remained on trial for >6 months, with two (2)
patients being on trial for more than 10 months.
Six (6) patients have now recorded a partial response as best response, with the remaining
eight (8) recording stable disease.
6 and 8 presumably that’s the 14 patients in question from 1b trail
No mention of any deaths …
These response rates are substantially higher than predicted from historical studies of
gemcitabine and Abraxane treatment alone.
And importantly, … Three (3) patients remain on trial from the Phase 1b cohort.
.
- Forums
- ASX - By Stock
- ATX
- Ann: Update on ACCENT Trial in Pancreatic Cancer
Ann: Update on ACCENT Trial in Pancreatic Cancer, page-7
-
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATX (ASX) to my watchlist
|
|||||
Last
8.8¢ |
Change
-0.012(12.0%) |
Mkt cap ! $24.13M |
Open | High | Low | Value | Volume |
12.0¢ | 13.5¢ | 8.6¢ | $614.5K | 5.826M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 122997 | 8.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.4¢ | 11000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 122997 | 0.088 |
1 | 10000 | 0.087 |
1 | 30000 | 0.086 |
1 | 100000 | 0.085 |
1 | 10000 | 0.080 |
Price($) | Vol. | No. |
---|---|---|
0.094 | 11000 | 1 |
0.095 | 47952 | 1 |
0.098 | 55000 | 1 |
0.105 | 25000 | 1 |
0.115 | 70000 | 1 |
Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
Featured News
ATX (ASX) Chart |